CSL Vifor and Fresenius Kabi Receive the NMPA’s Approval for Ferinject to Treat Iron Deficiency in Adult Patients
- The NMPA has approved Ferinject for iron deficiency in adult patients for whom oral iron preparations are ineffective & clinically need to deliver iron rapidly. Ferinject has received marketing authorization in 85 countries globally
- The authorization was based on the P-III trial (VIT-IRON-2011-004) which showed that Ferinject was an effective & well-tolerated alternative to iron sucrose for iron deficiency anemia that can provide an improved Hb response & correction of iron deficiency
- The product is expected to be available in H1’23 with NRDL listing anticipated in Jan 2024. The approval may also benefit the Chinese healthcare system & among others through the implementation of a more effective patient blood management (PBM)
Ref: Vifor pharma | Image: CSL Vifor
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.